Karo is a pan-European consumer healthcare company headquartered in Stockholm, Sweden. The company operates a product portfolio spanning core categories such as Skin Health, Foot Health, and Intimate Health, as well as Digestive Health and Vitamins, Minerals & Supplements.

Under EQT’s ownership since 2019, Karo has undergone a strategic repositioning, shifting from a specialty pharmaceutical company focused on the Nordics into becoming a pan-European pure-play consumer healthcare platform. During this time, with M&A having been a cornerstone of Karo’s growth strategy, Karo completed eight acquisitions from industry players which have enriched Karo’s portfolio, strengthened its presence in key markets, and accelerated its entry into new geographies.

Related article

EQT makes buy-out offer for Karo Pharma

Private equity fund EQT has made a cash offer for the remaining shares in Swedish biopharmaceuticals group Karo Pharma. EQT currently owns 86% of Karo Pharma. The total value of the offer is 2.23 billion Swedish crowns ($215.15 million), valuing Karo Pharma at 16.4 billion, EQT subsidiary Karo Intressenter said in a statement. In 2018, […]

“With KKR as our new owner, we are entering an exciting next phase in our journey. Their global reach, deep sector understanding, and long-term approach make them the ideal strategic partner as we continue to invest in our brands, expand into new markets and meet the evolving health needs of consumers,” says Christoffer Lorenzen, CEO of Karo Healthcare.

The transaction is subject to customary regulatory conditions and approvals and is expected to close in the coming months.